Oxford Cancer Biomarkers announces European expansion of life-saving chemotherapy toxicity test and independent, real-world evidence of patient benefit

OXFORD, UK – Oxford Cancer Biomarkers Ltd (OCB) announces that ToxNav®, its proprietary pharmacogenomics test for predicting genetic susceptibility to toxicity from fluoropyrimidine-based chemotherapy, is now available to clinicians in Europe following registration in the EUDAMED database. The European Medicines Agency recommends DPYD testing before all fluoropyrimidine-based chemotherapy (including 5-FU, Capecitabine and tegafur).

OCB also reports publication of an independent study by Oxford University Hospitals NHS Trust and Oxford University, representing the first evidence in the real world setting that upfront screening for DPYD variants using ToxNav® can help reduce the risk of potentially life-threatening toxicity and side-effects that negatively impact quality of life and tolerance to treatment. ToxNav® testing and dose management as guided by the ToxNav® test report can also lead to substantial hospital cost savings for cancer patients treated with fluoropyrimidine chemotherapy, including over £20,000 of cost savings for those with critical toxicity risk.

The results of the analysis are published in BMC Cancer.

For more information see the attached pdf